Inclisiran : Indications and use

This table provides a comprehensive summary of the recommendations, indications, and clinical evidence regarding the use of Inclisiran (Leqvio, Novartis) for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia in adults. Inclisiran, a novel cholesterol-lowering therapy, has been under evaluation for its efficacy and safety in specific populations, especially those with a history of cardiovascular events. The table delineates the specific conditions under which Inclisiran is recommended, its mechanism of action, and the current clinical evidence supporting its use.

Topic	Information/Recommendation
Recommendation of use	Inclisiran Use: For treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults. Criteria: - History of cardiovascular events: acute coronary syndrome, coronary or other arterial revascularisation procedures, coronary heart disease, ischaemic stroke, peripheral arterial disease. - LDL-C concentrations persistently 2.6 mmol/l or more, despite max tolerated lipid-lowering therapy. - The company provides inclisiran under a commercial arrangement.
Recommendation	Inclisiran Use: Only in research for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults without a history of cardiovascular events. The research is in the form of a clinical trial currently in development.
Recommendation	Existing treatments started in the NHS before this guidance are unaffected. Treatments outside these recommendations may continue without...

Try our Free Plan to get the full article.